Home / Congress Presentations / C3G and Primary IC-MPGN / American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2026
Landing
American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2026
Pegcetacoplan population pharmacokinetic and exposure-response in pediatric and adult patients with C3G and primary immune-complex membranoproliferative glomerulonephritis
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.